Sanofi Says Next-Gen COVID Booster Shot Has Potential Against Main Variants
PARIS (Reuters) – French drugmaker Sanofi said on Monday an upgraded version of the COVID-19 vaccine candidate it is developing with GSK showed potential in two trials to protect against the virus’s main variants of concern, including the Omicron BA.1 and BA.2 strains, when used as a booster shot.
While the two companies’ first experimental COVID shot is undergoing review by the European Medicines Agency, Sanofi and GSK have continued work on a vaccine that is molded on the now-supplanted Beta variant, hoping still that it will confer broad protection against future viral mutations.
The vaccine is based on a recombinant protein subunit and GSK’s AS03 adjuvant, which has previously been used in licensed flu vaccines.
Sanofi said in a press release (https://bit.ly/39gNxFM) this new vaccine candidate was shown to significantly boost antibody levels against a number of variants of concern, when given to trial participants who had an initial course of mRNA vaccines made by BioNTech-Pfizer and Moderna.
In a separate trial conducted by a French hospitals network, Sanofi’s Beta-adapted booster shot triggered a higher immune response than Sanofi’s first-generation shot or Pfizer-BioNTech’s established vaccine in previously vaccinated volunteers.
“The Beta variant expresses similar mutations across multiple variants of concern, including Omicron, making it a strong vaccine candidate to confer broad protection against multiple strains of COVID-19,” said Thomas Triomphe, the head of Sanofi’s vaccine business.
Highlighting the need for vaccine makers to address new variants of concern in a saturated COVID vaccine market, Valneva on Friday said it was in talks to try to salvage a supply agreement that the European Commission cancelled.
Valneva’s product, an inactivated-virus vaccine, is based on the original virus found in the Chinese city of Wuhan, similar to BioNTech-Pfizer and Moderna’s dominant first-generation shots.
Source: Read Full Article